RightFit
RecruitingPhase 4

Aspirin and Preeclampsia

Aspirin to Prevent Cardiac Dysfunction in Preeclampsia

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 45 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Visits mentioned: 6 visits
  • Procedures mentioned: Blood draws

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "The patient will be subjected to a total of 2 such blood draws- a single draw at screening, one at their 6 month postpartum visit."
  • "The member of the study team carrying out the blood draw will immediately label the specimen in the presence of the subject, after the collection and before leaving the patient's bedside, room, cubicle or surgical suite."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether aspirin after birth lowers Activin A levels and improves a measure of heart function called GLS. It is for pregnant adults ages 18 to 45 with preeclampsia, a pregnancy condition that causes high blood pressure, who are coming in to deliver one baby.

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve (GLS) in preeclamptic patients.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Are pregnant and 18 to 45 years old.
  • Have been diagnosed with preeclampsia.
  • Are coming in to deliver one baby.

Who can't join

  • Are already in labor or are pregnant with more than one baby.
  • Have an existing heart muscle disease, long-term high blood pressure, heart disease from poor blood flow, heart valve disease, lung disease, diabetes, or long-term kidney disease.
  • Plan to give birth outside the study hospital.
  • Are in another trial that the lead researcher thinks could affect taking the study medicine.
  • Are allergic to aspirin, have a clear medical need for it, or have a medical reason not to take it.
  • Have a serious condition that could make following the study plan difficult, such as stomach ulcers, past bleeding in the digestive tract, or a bleeding disorder.
  • Take or plan to take nonsteroidal anti-inflammatory drugs (NSAIDs), a type of pain and swelling medicine, during the study.
  • Cannot give consent to join the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Pregnant Adults between 18 and 45 years of age 2. Diagnosed with preeclampsia 3. Presenting for delivery with a singleton gestation. Exclusion Criteria: 1. We will exclude patients in labor 2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation 3. Plan to deliver outside of the participating site 4. Co-enrolled in other trials that might affect the patients taking the study medication, as determined by the PI. 5. Aspirin allergy 6. Clear indication for aspirin therapy or contraindication to aspirin therapy 7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders) 8. Currently or planning on taking any nonsteroidal anti-inflammatory drugs while they are participating in this study. 9. Those who cannot provide consent

Study sites (1)

IL